Clinical trial · Observational
MRI and Bladder Cancer Chemotherapy
Pilot Study of Role of MRI in Neoadjuvant Chemotherapy for Bladder Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective study of pretreatment DW-MRI to identify potential imaging biomarkers predictive of response to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. Target enrollment of this study is 40 patients. Patients will first undergo baseline DW-MRI of the Abdomen and Pelvis prior to beginning standard treatment with neoadjuvant cisplatin-based chemotherapy after which DW-MRI will be repeated to assess for response or progression. Patients who remain eligible for surgery will proceed to standard radical cystectomy with pelvic lymph node dissection. DW-MRI metrics including apparent diffusion coefficient (ADC) values will be correlated to pathologic response rate in the radical cystectomy specimen to identify imaging markers predictive of response.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Invasive Bladder Cancer | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Complete pathologic response
- timeFrame
- Under one year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed muscle invasive urothelial carcinoma of the bladder * Clinical stage T2-T4a N0/X M0 disease * Age ≥ 18 years of age * Medically appropriate candidate for radical cystectomy, as per NYU Attending Urologic Oncologist * Medically appropriate candidate for cisplatin-based neoadjuvant chemotherapy as per NYU Attending Medical Oncologist * If female of childbearing potential, pregnancy test is negative Exclusion Criteria: * Prior systemic chemotherapy (prior intravesical therapy is allowed) * Prior radiation therapy to the bladder * Medical contraindication to cisplatin-based neoadjuvant chemotherapy as determined by NYU Attending Medical Oncologist * Concomitant use of any other investigational drugs * Inability to tolerate MRI including conditions such as claustrophobia or inability to lay flat for \> 45 minutes. * Presence of pacemaker/ICD or perfusion pumps * Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial heart, valves with steel parts, metal fragments, shrapnel, bullets, tattoos near the eye, or steel implants. * Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study
References
Publications (0)
Data not yet available